Enhanced Remdesivir Analogues to Target SARS-CoV-2

Ryuichi Majima, Tiffany C. Edwards, Christine D. Dreis, Robert J. Geraghty, Laurent F. Bonnac

Research output: Contribution to journalArticlepeer-review


We report the short synthesis of novel C-nucleoside Remdesivir analogues, their cytotoxicity and an in vitro evaluation against SARS-CoV-2 (CoV2). The described compounds are nucleoside analogues bearing a nitrogen heterocycle as purine analogues. The hybrid structures described herein are designed to enhance the anti-CoV2 activity of Remdesivir. The compounds were evaluated for their cytotoxicity and their anti-CoV2 effect. We discuss the impact of combining both sugar and base modifications on the biological activities of these compounds, their lack of cytotoxicity and their antiviral efficacy.

Original languageEnglish (US)
Article number2616
Issue number6
StatePublished - Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.


  • C-nucleoside
  • SARS-CoV-2
  • antiviral
  • phosphate prodrug

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Enhanced Remdesivir Analogues to Target SARS-CoV-2'. Together they form a unique fingerprint.

Cite this